Bill > HB1470

This bill aims to establish a subscription model for GLP-1 agonists (a type of medication used to treat obesity) in Pennsylvania's public assistance program. Specifically, the bill requires the state department to seek a federal waiver from the Centers for Medicare and Medicaid Services to create value-based arrangements with drug manufacturers through supplemental rebate agreements. The bill defines GLP-1 agonists as medications that affect the body by triggering insulin release, blocking glucagon secretion, slowing stomach emptying, and increasing feelings of fullness after eating. Under the proposed supplemental rebate agreement, the Commonwealth would pay an agreed amount per treatment up to a certain cap, after which treatments would be provided at no cost to the state. The department is also required to develop regulations to implement this new approach, and the bill will take effect 60 days after its passage. The goal appears to be creating a more cost-effective and sustainable way of providing obesity treatment medications through the public assistance program.

Health and Social Services

https://www.legis.state.pa.us/cfdocs/billinfo/bill_history.cfm?syear=2025&sind=0&body=H&type=B&bn=1470